Skip to main content

Table 3 MCL1, BCL2, BCL-XL gene expression in AML cases (n = 70)

From: Spontaneous apoptosis and BCL2 gene expression as predictors of early death and short overall survival in acute leukemia patients: a prospective, case cohort study

  MCL1 BCL2 BCL-XL
Negative (n = 24) Positive (n = 46) P Negative (n = 20) Positive (n = 50) P Negative (n = 24) Positive (n = 46) P
FAB
 APL (n = 11)* 5 6 NS 5 6 NS 5 6 NS
 Non-APL (n = 59) 19 40 15 44 19 40
Performance status
0/1 (n = 33) 14 19 NS 8 25 NS 16 17 NS
2/3 (n = 37) 10 27 12 25 8 29
Early death
 No (n = 48) 17 31 NS 10 38 0.02 17 31 NS
 Yes (n = 20) 7 13 10 10 7 13
Apoptosis medians (ranges)
 Annxine V 3.8 (0.4–9.1) 4.9 (0.3–13.6) NS 2.7 (0.4–8.4) 4.8 (0.3–13.6) 0.03 3.8 (0.4–9.5) 4.5 (0.3–13.6) NS
 Anx&PI 3.4 (0.6–13.9) 5.5 (0.6–17.1) NS 2.5 (0.6–7.8) 5.5 (0.6–17.1) 0.003 3.5 (0.6–12.3) 5.5 (0.6–17.1) NS
 Total apoptosis 8.3 (1.7–18.6) 10.4 (2.9–19.3) NS 4.6 (1.7–14.3) 11.1 (2.9–19.3) 0.001 8.3 (1.7–17.7) 10.4 (2.9–19.3) NS
  1. *Acute Promyelocytic Leukemia
  2. Two patient left hospital at the induction phase
  3. Annexine V and Propidium Iodide
  4. Mann–Whitney’s U test, Pearson Chi-square or Fisher exact test was carried out as specified in the method section
  5. Significant P values are written in bold; NS, not significant